All In Biotech

Drug Trial Radar · NCT07697833

Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients

Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Patients With Heart Failure and Reduced Ejection Fraction: Randomized, Placebo-controlled, Parallel-group, Double-blind Trial

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

May 15, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
National Institute of Cardiovascular Diseases, PakistanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Horizon Pharmaceuticals
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the effectiveness and safety of Vericiguat with Standard Medical Treatment in Patients with Heart Failure and Reduced Ejection Fraction

Conditions

  • Heart Failure With Reduced Ejection Fraction (HFrEF)

Interventions

  • Vericiguat tabletDrug

    Vericiguat 10 mg (titrated from 2.5 mg, to 5 mg, and to 10 mg), on a background of standard of care

  • PlaceboDrug

    Participants will receive a matching placebo tablet. The placebo will follow the same dosing schedule as the study drug (2.5 mg, 5 mg, and 10 mg) to maintain blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quality of life using Kansas City Cardiomyopathy Questionnaire (KCCQ-12)Time frame: Baseline to Month 6

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.